Bi-paratopic and multivalent human VH domains neutralize SARS-CoV-2 by targeting distinct epitopes within the ACE2 binding interface of Spike

Colton J. Bracken; Shion A. Lim; Paige Solomon; Nicholas J. Rettko; Duy P. Nguyen; Beth Shoshana Zha; Kaitlin Schaefer; James R. Byrnes; Jie Zhou; Irene Lui; Jia Liu; Katarina Pance; - QCRG Structural Biology Consortium; Xin X. Zhou; Kevin K. Leung; James A. Wells.
Preprint en Inglés | PREPRINT-BIORXIV | ID: ppbiorxiv-242511

Documentos relacionados

  1. Bi-paratopic and multivalent VH domains block ACE2 binding and neutralize SARS-CoV-2.
  2. Bi-paratopic and multivalent human VH domains neutralize SARS-CoV-2 by targeting distinct epitopes within the ACE2 binding interface of Spike.
  3. Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy.
  4. Screening and Characterization of Shark-Derived VNARs against SARS-CoV-2 Spike RBD Protein.
  5. A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern.
  6. Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations.
  7. Structure basis of two nanobodies neutralizing SARS-CoV-2 Omicron variant by targeting ultra-conservative epitopes.
  8. A potent and broad neutralization of SARS-CoV-2 variants of concern by DARPins.
  9. Potent cross-reactive antibodies following Omicron breakthrough in vaccinees.
  10. Neutralization of SARS-CoV-2 requires antibodies against conformational receptor-binding domain epitopes.